Market Divide in Canine Longevity

This contrast shows that the real split in canine longevity is not just science, it is treatment economics and clinical risk. Loyal is building a repeat prescription business that fits normal vet workflows, with daily pills or periodic injections sold like other chronic animal medicines. Rejuvenate Bio is pursuing gene therapy for specific age linked diseases, which could deliver longer lasting effects from a single treatment but asks owners, vets, and regulators to accept a much bigger upfront decision.

• Rejuvenate Bio is developing separate gene therapy programs for canine mitral valve disease and osteoarthritis. The osteoarthritis program has already attracted an unnamed large animal health partner, and the mitral valve program previously partnered with Phibro, which suggests strategic interest but also a commercialization path likely built around specialty use, not broad preventive prescribing.
  1 rejuvenatebio 6 businesswire 7 rejuvenatebio
• Loyal’s products are designed to slot into routine care for generally healthy older dogs. LOY-002 is a daily pill for senior dogs, LOY-001 is an injection given every few months, and both are being advanced through the FDA’s expanded conditional approval path for lifespan extension. Loyal says LOY-001 received an RXE milestone in 2023 and LOY-002 received one in February 2025.
  2 loyal 3 loyal 4 loyal 5 sacra
• That creates a practical market divide. A one time gene therapy makes the most sense when a dog already has a serious condition like valve disease or painful joint degeneration. A lower priced chronic drug is easier to position earlier, across a much wider base of aging dogs, which matters if the goal is building a large recurring revenue business through primary care vets.
  2 loyal 3 loyal 4 loyal 5 sacra 6 businesswire 7 rejuvenatebio

Going forward, the likely shape of the category is gene therapy for high severity disease pockets, and small molecule longevity drugs for broad preventive use. If Loyal keeps converting FDA milestones into launch readiness, it can define the default prescribing habit in canine aging before one time therapies become common outside specialist settings.